You are here

  • Home
  • Archive
  • Volume 30, Issue Suppl 3
  • 323 ENGOT-en9/LEAP-001: a phase 3 study of first-line pembrolizumab plus lenvatinib compared with chemotherapy in advanced or recurrent endometrial cancer

Article metrics

Article menu

Download PDFPDF

Poster
IGCS20_1346
323 ENGOT-en9/LEAP-001: a phase 3 study of first-line pembrolizumab plus lenvatinib compared with chemotherapy in advanced or recurrent endometrial cancer
Free

 

Online download statistics by month:

Online download statistics by month: November 2020 to April 2024

AbstractFullPdf
Nov 202042010
Dec 20204609
Jan 20213206
Feb 20212505
Mar 20214408
Apr 20214708
May 20212609
Jun 20214012
Jul 2021005
Aug 20211010
Sep 2021008
Oct 202168015
Nov 202164019
Dec 20216003
Jan 20227403
Feb 20226808
Mar 20223604
Apr 20223403
May 20224207
Jun 20224807
Jul 20225602
Aug 20226603
Sep 202234010
Oct 20222404
Nov 20222602
Dec 20223503
Jan 20232201
Feb 202310201
Mar 20231902
Apr 2023402
May 20231001
Jun 20232201
Jul 20231805
Aug 20234004
Sep 20232603
Oct 20233203
Nov 20234602
Dec 20235300
Jan 2024800
Feb 20242802
Mar 20242902
Apr 20241603
Total14770215